{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:26:49Z","timestamp":1786991209328,"version":"build-2736575974"},"reference-count":90,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaad.2024.03.059","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T15:37:29Z","timestamp":1718206649000},"page":"985-998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Psoriatic arthritis: A comprehensive review for the dermatologist\u2013Part II: Screening and management"],"prefix":"10.1016","volume":"92","author":[{"given":"Scott A.","family":"Elman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes M.","family":"Perez-Chada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2024.03.059_bib1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jaad.2014.12.008","article-title":"Psoriatic arthritis: it's as easy as \u201cPSA.\u201d","volume":"72","author":"Cohen","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.03.059_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2007.04.001","article-title":"The PASE\u00a0questionnaire: pilot-testing a psoriatic arthritis screening\u00a0and evaluation tool","volume":"57","author":"Husni","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.03.059_bib3","first-page":"469","article-title":"Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire","volume":"27","author":"Ibrahim","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2024.03.059_bib4","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3899\/jrheum.101117","article-title":"Toronto psoriatic arthritis screening (ToPAS) questionnaire: a report from the GRAPPA 2009 annual meeting","volume":"38","author":"Chandran","year":"2011","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.03.059_bib5","first-page":"597","article-title":"Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care","volume":"56","author":"Karreman","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.jaad.2024.03.059_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/bjd.12748","article-title":"Diagnosing and treating psoriatic arthritis: an update","volume":"170","author":"Boehncke","year":"2014","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.03.059_bib7","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/rheumatology\/key314","article-title":"Psoriatic arthritis screening: a systematic review and meta-analysis","volume":"58","author":"Iragorri","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jaad.2024.03.059_bib8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjd.14929","article-title":"Comparison of four validated psoriatic arthritis screening tools in diagnosing psoriatic arthritis in patients with psoriasis (COMPAQ Study)","volume":"176","author":"Mishra","year":"2017","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2024.03.059_bib9","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.03.059_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.03.059_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2024.03.059_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2474-14-101","article-title":"The TICOPA protocol (tight control of psoriatic arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis","volume":"14","author":"Coates","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jaad.2024.03.059_bib13","first-page":"10","article-title":"Report of the skin research working groups from the GRAPPA 2020 annual meeting","volume":"97","author":"Perez-Chada","year":"2021","journal-title":"J Rheumatol Suppl"},{"issue":"9","key":"10.1016\/j.jaad.2024.03.059_bib14","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/annrheumdis-2018-215003","article-title":"The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies","volume":"78","author":"Kavanaugh","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"93","key":"10.1016\/j.jaad.2024.03.059_bib15","first-page":"S48","article-title":"Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review","volume":"5","author":"Smolen","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl2","key":"10.1016\/j.jaad.2024.03.059_bib16","doi-asserted-by":"crossref","first-page":"ii49","DOI":"10.1136\/ard.2004.034165","article-title":"Psoriatic arthritis assessment tools in clinical trials","volume":"64","author":"Mease","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.03.059_bib17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"8","key":"10.1016\/j.jaad.2024.03.059_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.03.059_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-020-4097-6","article-title":"Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)","volume":"21","author":"Mulder","year":"2020","journal-title":"Trials"},{"issue":"5","key":"10.1016\/j.jaad.2024.03.059_bib20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.03.059_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/ard.2009.113308","article-title":"Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis","volume":"69","author":"Lie","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jaad.2024.03.059_bib22","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/rheumatology\/ken059","article-title":"Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs","volume":"47","author":"Cantini","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.jaad.2024.03.059_bib23","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.jaad.2024.03.059_bib24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the\u00a0treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jaad.2024.03.059_bib25","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.03.059_bib26","first-page":"1025","article-title":"Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity","volume":"58","author":"Landew\u00e9","year":"2019","journal-title":"Rheumatol (United Kingdom)"},{"issue":"2","key":"10.1016\/j.jaad.2024.03.059_bib27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.03.059_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10067-014-2830-9","article-title":"Methotrexate revisited: considerations for subcutaneous administration in RA","volume":"34","author":"Jay","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.03.059_bib29","first-page":"1017","article-title":"Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature","volume":"27","author":"Visser","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.03.059_bib30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10067-014-2546-x","article-title":"Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort","volume":"33","author":"Nikiphorou","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.03.059_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202641","article-title":"Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials","volume":"73","author":"Goulabchand","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jaad.2024.03.059_bib32","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2024.03.059_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jaad.2024.03.059_bib34","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jaad.2024.03.059_bib35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2024.03.059_bib36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial","volume":"56","author":"Gladman","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.jaad.2024.03.059_bib37","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2024.03.059_bib38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/annrheumdis-2014-eular.3618","article-title":"OP0252 adalimumab serum concentrations in patients with\u00a0rheumatoid arthritis or psoriatic arthritis taking concomitant DMARD therapy","volume":"73","author":"Krieckaert","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.03.059_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001047","article-title":"Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial","volume":"6","author":"Ducourau","year":"2020","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.jaad.2024.03.059_bib40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jaad.2024.03.059_bib41","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.40508","article-title":"Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database","volume":"70","author":"Clowse","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.03.059_bib42","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.jaad.2024.03.059_bib43","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.jaad.2024.03.059_bib44","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9894","key":"10.1016\/j.jaad.2024.03.059_bib45","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaad.2024.03.059_bib46","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2024.03.059_bib47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.03.059_bib48","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jaad.2024.03.059_bib49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10230","key":"10.1016\/j.jaad.2024.03.059_bib50","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"issue":"10230","key":"10.1016\/j.jaad.2024.03.059_bib51","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jaad.2024.03.059_bib52","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.03.059_bib53","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","article-title":"Efficacy and safety of guselkumab, an interleukin-23p 19\u2013specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis","volume":"73","author":"McInnes","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.03.059_bib54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2024.03.059_bib55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"Ostor","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jaad.2024.03.059_bib56","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23\u00a0inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10370","key":"10.1016\/j.jaad.2024.03.059_bib57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"issue":"10370","key":"10.1016\/j.jaad.2024.03.059_bib58","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jaad.2024.03.059_bib59","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"issue":"9999","key":"10.1016\/j.jaad.2024.03.059_bib60","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2024.03.059_bib61","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2015-eular.2276","article-title":"THU0421 secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study (future 2)","volume":"74","author":"Kirkham","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2024.03.059_bib62","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.03.059_bib63","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"10.1016\/j.jaad.2024.03.059_bib64","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaad.2024.03.059_bib65","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"Van Der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2024.03.059_bib66","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-2-1","article-title":"Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors","volume":"9","author":"Fieldhouse","year":"2020","journal-title":"Drugs Context"},{"issue":"7","key":"10.1016\/j.jaad.2024.03.059_bib67","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1093\/rheumatology\/keab819","article-title":"New-onset inflammatory bowel diseases among IL-17 inhibitors-treated patients: results from the case-control MISSIL study","volume":"61","author":"Letarouilly","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jaad.2024.03.059_bib68","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.03.059_bib69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jaad.2024.03.059_bib70","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.20413","article-title":"Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study","volume":"185","author":"Gottlieb","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.03.059_bib71","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jaad.2024.03.059_bib72","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.03.059_bib73","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2024.03.059_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000669","article-title":"Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies","volume":"4","author":"Gladman","year":"2018","journal-title":"RMD Open"},{"issue":"suppl 9","key":"10.1016\/j.jaad.2024.03.059_bib75","article-title":"16-Week results from FOREMOST, a placebo-controlled study involving oligoarticular psoriatic arthritis treated with apremilast [abstract]","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.03.059_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-014-0005-4","article-title":"Apremilast: a phosphodiesterase 4 inhibitor for the treatment of psoriatic arthritis","volume":"1","author":"Mease","year":"2014","journal-title":"Rheumatology and Therapy"},{"issue":"3","key":"10.1016\/j.jaad.2024.03.059_bib77","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/1573397115666181130094455","article-title":"Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis","volume":"15","author":"Metyas","year":"2019","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.jaad.2024.03.059_bib78","first-page":"97","article-title":"Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives","volume":"9","author":"Ly","year":"2019","journal-title":"Psoriasis (Auckl)"},{"issue":"16","key":"10.1016\/j.jaad.2024.03.059_bib79","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jaad.2024.03.059_bib80","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jaad.2024.03.059_bib81","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2024.03.059_bib82","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(21)00010-2","article-title":"Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.03.059_bib83","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"Supplement_2","key":"10.1016\/j.jaad.2024.03.059_bib84","doi-asserted-by":"crossref","first-page":"S746","DOI":"10.1093\/ecco-jcc\/jjz186","article-title":"Efficacy of JAK inhibitors in Crohn's disease","volume":"14","author":"Rogler","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"13","key":"10.1016\/j.jaad.2024.03.059_bib85","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2024.03.059_bib86","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2024.03.059_bib87","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/annrheumdis-2020-eular.1229","article-title":"Efficacy and safety of updadacitinib in patients with active PsoriaticArthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs: a double-blind, randomized controlled phase 3 trial","volume":"79","author":"Genovese","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jaad.2024.03.059_bib88","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jaad.2024.03.059_bib89","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2024.03.059_bib90","first-page":"31","article-title":"Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives","volume":"8","author":"Noisette","year":"2018","journal-title":"Psoriasis (Auckl)"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224008521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224008521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T23:54:07Z","timestamp":1744847647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224008521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0190962224008521"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.03.059","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriatic arthritis: A comprehensive review for the dermatologist\u2013Part II: Screening and management","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.03.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.03.058","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}